tas0612
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04586270)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- p90RSKINHIBITOR
p90RSK inhibitor
- Ribosomal protein S6 kinase (P70S6K)INHIBITOR
Ribosomal protein S6 kinase (P70S6K) inhibitor
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
- Ribosomal protein S6 kinase 1INHIBITOR
RPS6KB1 inhibitor
- Serine/threonine-protein kinase AKT2INHIBITOR
AKT2 inhibitor
- Ribosomal protein S6 kinase alpha 1INHIBITOR
RPS6KA1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C)NCCNc1ccc(C2=NN=C(C(F)(F)F)C2)nc1C1CCN(c2ncnc3c2C(C)(C)C(=O)N3)CC1- Mol. weight
- 571.65 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650277 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04586270 | Phase 1 | Oct 31, 2020 | Otsuka |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1